Genmab — December 2016
-
God morgen.
-
God morgen. Klokken er 23:30 i San Diego. Så vi for vel først nyt derfra om 10-12 timer?
-
Daratumumab Is Effective in the Treatment of Refractory Post-Transplant Autoimmune Hemolytic Anemia: A Pediatric Case Report http://www.bloodjournal.org/content/128/22/4819?sso-checked=true
-
"
Conclusion: In our patient with post-HSCT AIHA who was refractory to multiple therapies, daratumumab dramatically decreased her pRBC transfusion requirement; laboratory parameters indicate this was a result of decreased active hemolysis. Further study is warranted to assess whether CD38 targeting is a safe and effective treatment for patients with refractory post-HSCT AIHA". -
Tusinde tak GB.
-
Suverænt link Fafar. Tak for det. Det sender jeg til Lau og Beskos.
-
Vedr. AIHA: 2% af AML-patienter får denne komplikation efter 1. transplantation, og 10% efter 2. transplantation. Er der nogen der har tal på hvor mange AML-patienter der får knoglemarvstransplantation. På kræftens bekæmpelse skriver de "et stigende antal". Og tak for artiklen George.
-
Yesterdays symposium discussed the various treatment options and therapeutic decisions faced by clinicians treating myeloma. It was clear even the experts didn’t always agree on what best practice is, that it is different for each patient and that clinical judgement is needed for each decision.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind